Invivyd, Inc. Announces Promising Phase 1/2 Data for VYD2311 Monoclonal Antibody Candidate in COVID-19 Prevention and Treatment
26/6 13:11
Invivyd reports positive Phase 1/2 results for VYD2311, showing safety, long half-life, and potential for effective COVID-19 prevention....